Option Care Health, Inc. (NASDAQ:OPCH) Given Average Rating of “Moderate Buy” by Brokerages

Option Care Health, Inc. (NASDAQ:OPCH) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $33.00.

Several equities analysts have recently issued reports on OPCH shares. JMP Securities reiterated a “market outperform” rating and set a $30.00 price target (down from $31.00) on shares of Option Care Health in a research report on Friday, January 10th. Barrington Research lifted their target price on Option Care Health from $33.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, February 27th. Jefferies Financial Group raised shares of Option Care Health from a “hold” rating to a “buy” rating and upped their price target for the company from $26.00 to $35.00 in a report on Thursday, January 23rd. JPMorgan Chase & Co. lifted their price objective on shares of Option Care Health from $40.00 to $41.00 and gave the stock an “overweight” rating in a research note on Thursday, March 6th. Finally, Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and increased their target price for the company from $26.00 to $33.00 in a research note on Monday, January 13th.

Option Care Health Trading Down 2.0 %

Option Care Health stock opened at $32.87 on Thursday. Option Care Health has a 12-month low of $21.39 and a 12-month high of $35.53. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. The stock has a market capitalization of $5.40 billion, a PE ratio of 27.62, a price-to-earnings-growth ratio of 2.30 and a beta of 1.07. The firm has a 50 day simple moving average of $33.00 and a 200-day simple moving average of $28.50.

Insider Transactions at Option Care Health

In related news, insider Michael Bavaro sold 30,996 shares of the firm’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $33.26, for a total value of $1,030,926.96. Following the completion of the transaction, the insider now owns 44,974 shares of the company’s stock, valued at approximately $1,495,835.24. This trade represents a 40.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.64% of the stock is currently owned by insiders.

Institutional Trading of Option Care Health

Hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Option Care Health by 84.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 70,119 shares of the company’s stock worth $2,195,000 after acquiring an additional 32,142 shares in the last quarter. Martingale Asset Management L P acquired a new position in shares of Option Care Health in the 3rd quarter valued at about $287,000. Atom Investors LP purchased a new stake in shares of Option Care Health in the third quarter worth approximately $485,000. HighTower Advisors LLC boosted its holdings in shares of Option Care Health by 10.0% during the third quarter. HighTower Advisors LLC now owns 401,061 shares of the company’s stock worth $12,514,000 after purchasing an additional 36,308 shares during the period. Finally, Janus Henderson Group PLC grew its position in Option Care Health by 4.1% during the third quarter. Janus Henderson Group PLC now owns 214,081 shares of the company’s stock valued at $6,699,000 after purchasing an additional 8,467 shares in the last quarter. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.